Covaxin, developed by India’s Hyderabad-based Bharat Biotech, provided only 50 percent protection against the Covid-19 infection during the second wave of the pandemic in India, according to the first real-world assessment published in The Lancet Infectious Diseases journal on Wednesday.

According to the study which assessed 2,714 hospital workers from the All India Institute of Medical Sciences (AIIMS) in New Delhi, from April 15 to May 15, 2021, who were symptomatic and underwent RT-PCR testing for Covid-19.

The study on the efficacy of Covaxin has found that it is only 50% effective against symptomatic Covid-19, whereas it was declared 77.8% efficacy by Bharat Biotech as claimed in its phase 3 trials.

Similarly, on July 2021 a study found the efficacy of Covidshield to be 63.1% effective in comparison to 79% efficacy claimed during the phase 3 trial.

The Lancet study does not estimate vaccine efficacy against hospitalisation, severe disease and death.

Advertisements | 5E For Success